Annual report for 2021
April 2022
Section I important tips, contents and definitions
The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee that the contents of the annual report are true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities.
Wang Jianping, the person in charge of the company, Xu Rongyi, the person in charge of accounting, and Yan Xiaomin, the person in charge of the accounting organization (the person in charge of Accounting), declare that they guarantee the authenticity, accuracy and completeness of the financial report in this annual report.
All directors have attended the meeting of the board of directors to consider this report.
This annual report involves forward-looking statements such as future plans, which does not constitute the company’s substantive commitment to investors and related persons. Investors and related persons should maintain sufficient risk awareness and understand the differences between plans, forecasts and commitments.
In Section III “management discussion and analysis” of this report, “Xi. Prospect of the company’s future development”, the company analyzes the risks and countermeasures that the company may face in its operation. Please pay attention to it. The company plans not to distribute cash dividends, bonus shares or increase share capital with provident fund.
catalogue
Section I important tips, contents and definitions Section 2 company profile and main financial indicators Section III Management Discussion and Analysis Section IV corporate governance Section V environmental and social responsibility Section VI important matters 69 Section VII changes in shares and shareholders 89 Section VIII preferred shares 96 section IX relevant information of bonds 97 section x financial report ninety-eight
Directory of documents for future reference
1. Financial statements containing the signatures and seals of the person in charge of the company, the person in charge of accounting and the person in charge of accounting institutions. 2. The 2021 annual audit report with the seal of the accounting firm and the signature and seal of the certified public accountant. 3. The originals of all company documents and announcements publicly disclosed on the website designated by the CSRC during the reporting period. Place of preparation of the above documents for future reference: Office of the board of directors of the company
interpretation
Explanatory item refers to the explanatory content
The company, the company and Hainan Haiyao Co.Ltd(000566) refer to Hainan Haiyao Co.Ltd(000566)
Xinxing Jihua Group Corporation Limited(601718) refers to Xinxing Jihua Group Corporation Limited(601718) Co., Ltd
CSRC refers to the China Securities Regulatory Commission
Shenzhen stock exchange refers to Shenzhen Stock Exchange
Pharmaceutical holding refers to Xinxing Jihua pharmaceutical Holding Co., Ltd
Huatong industry refers to Hainan Huatong Industry Co., Ltd
Kaizheng biology refers to Beijing Kaizheng bioengineering Development Co., Ltd
Nanfang Tongzheng refers to Shenzhen Nanfang Tongzheng Investment Co., Ltd
Haikou pharmaceutical factory refers to Haikou Pharmaceutical Factory Co., Ltd
Tiandi pharmaceutical refers to Chongqing Tiandi Pharmaceutical Co., Ltd
Shanghai lishengte and lishengte refer to Shanghai lishengte Medical Technology Co., Ltd
China antibody refers to China antibody Pharmaceutical Co., Ltd
Lianqiao Yaodu refers to Hunan Lianqiao Yaodu Pharmaceutical Co., Ltd
Yade technology refers to Chongqing Yade Technology Co., Ltd
Jiangsu hankuo refers to Jiangsu hankuo biology Co., Ltd
Kaiyuan pharmaceutical refers to Yancheng Kaiyuan Pharmaceutical Chemical Co., Ltd
Articles of association refers to Hainan Haiyao Co.Ltd(000566) articles of association
Company Law refers to the company law of the people’s Republic of China
GMP certification refers to the certification of drug production quality management practices
When applying for new drug registration, clinical trials (including bioequivalence tests) shall be conducted. Clinical trials of drugs refer to clinical trials, which must be approved by the State Food and drug administration, and must implement the code for quality management of clinical trials of drugs. The clinical trials were divided into phase I, II, III and IV.
The reporting period refers to the period from January 1, 2021 to December 31, 2021
Yuan and 10000 yuan refer to RMB yuan and 10000 yuan
Section II Company Profile and main financial indicators
1、 Company information
Stock abbreviation Hainan Haiyao Co.Ltd(000566) Stock Code: Hainan Haiyao Co.Ltd(000566)
Shenzhen Stock Exchange
Chinese name of the company Hainan Haiyao Co.Ltd(000566)
Chinese abbreviation of the company Hainan Haiyao Co.Ltd(000566)
Foreign name of the company (if any) Hainan Haiyao Co., Ltd. abbreviation of foreign name of the company (if any) Hainan Haiyao
Legal representative of the company: Wang Jianping
Registered address: No. 192, Nanhai Avenue, Xiuying District, Haikou City, Hainan Province
Postal code of registered address 570311
The historical change of the company’s registered address is not applicable
Office address: No. 192, Nanhai Avenue, Xiuying District, Haikou City, Hainan Province
Postal code of office address: 570311
Company website: www.haiyao.com com. cn.
E-mail Hainan Haiyao Co.Ltd(000566) @haiyao.com.cn.
2、 Contact person and contact information
Secretary of the board of directors and securities affairs representative
Name: Shi Lei, Wang Xiaosu
Contact address: No. 192, Nanhai Avenue, Xiuying District, Haikou City, Hainan Province
Tel: 089836380609
Fax: 089836380609
E-mail Hainan Haiyao Co.Ltd(000566) @haiyao.com.cn. Hainan Haiyao Co.Ltd(000566) @haiyao.com.cn.
3、 Information disclosure and preparation location
The website of the stock exchange where the company discloses the annual report Shenzhen Stock Exchange http://www.szse.cn.
The media name and website of the annual report disclosed by the company include securities times, China Securities News, Shanghai Securities News, securities daily and cninfo（ http://www.cn.info.com.cn. )
The company’s annual report is prepared at the office of the board of directors of the company
4、 Registration changes
Organization Code: 9146 Shenzhen Zhongheng Huafa Co.Ltd(000020) 1289453d
Changes in the company’s main business since its listing (if there is no change)
1. On August 8, 1992, it was reorganized and established on the basis of the former Haikou pharmaceutical factory with the approval of the Hainan Provincial joint stock pilot leading group office in document qiongguban Zi (1992) No. 10.
The company obtained the business license of enterprise legal person issued by Hainan Administration for Industry and Commerce on December 30, 1992. In December 1993, the State Securities Commission approved the issuance of public shares to the public with the approval of Zheng Jian FA Shen Zi (1993) No. 115 document, and it was listed on Shenzhen Stock Exchange in May 1994, with a registered capital of 14250000000 yuan. The controlling shareholder of the company is Haikou state owned Assets Administration Bureau. 2. On January 15, 1998, China Qingqi Group Co., Ltd. acquired 79173404 state shares and corporate shares of the company, accounting for 39.13% of the total share capital. Become the largest shareholder of the company. 3. On September 24, 2001, Shenzhen Nanfang Tongzheng Investment Co., Ltd. competed for the change of previous controlling shareholders of China Qingqi Group (if any) 37011575 state-owned legal person shares held by the company and pledged to Haikou state owned Assets Management Co., Ltd., accounting for 18.29% of the total share capital. On December 20, 2002, Shenzhen Nanfang Tongzheng Investment Co., Ltd. competed for 16198033 state-owned legal person shares held by Haikou state owned Assets Management Co., Ltd. according to law. After the equity transfer and transfer, Shenzhen Nanfang Tongzheng Investment Co., Ltd. held a total of legal person shares of the company
53209608 shares, accounting for 26.30% of the total share capital. Become the largest shareholder of the company. 4. On February 27, 2020, Nantong is transferring 203029776 shares of the company held by it (accounting for 15.20% of the total share capital of the company) to Hainan Huatong Industrial Co., Ltd; On March 13, 2020, Huatong industry transferred all the remaining bonds of Nanfang Tongzheng’s non-public issuance of exchangeable corporate bonds in 2017 and completed the conversion of 93960113 shares of the company’s shares, accounting for 7.03% of the company’s total share capital. On March 13, 2020, the controlling shareholder of the company was changed from Shenzhen Nanfang Tongzheng Investment Co., Ltd. to Hainan Huatong Industrial Co., Ltd
